CGCI: Cancer Genome Characterization Initiative

CGCI supports cutting-edge genomics research on adult and pediatric cancers. Researchers develop and apply advanced sequencing and other genome-based methods to identify novel genetic abnormalities in tumors. The extensive genetic profiles generated by CGCI may inform better cancer diagnosis and treatment.

Cancer Genome Characterization Initiative banner shows logo, genomics cartoon, and a boy with his dad. Links to program landing page.

News & Publications

May 13, 2016

A new funding opportunity aims to generate novel human tumor-derived culture models that will be made accessible to scientists around the world.

Most cancer cell lines that are commonly used in research labs today were established decades ago and have been propagated in culture for many...


Burkitt Lymphoma

The goal of the Burkitt Lymphoma Genome Sequencing Project (BLGSP) is to explore potential genetic changes in patients with Burkitt lymphoma (BL)Opens in a New Tab that could lead to better prevention, detection, and treatment of this rare and aggressive cancer.

HIV-Associated Cancers

The Office of Cancer Genomics (OCG)Opens in a New Tab, along with the Office of HIV and AIDS Malignancies (OHAM)Opens in a New Tab, initiated the HIV+ Tumor Molecular Characterization Project (HTMCP) to gain insight into the genetic events driving HIV-associated cancers and to determine why certain cancers, but not others, have higher incidences in HIV-positive patients.


CGCI developed the Medulloblastoma Project to apply newly emerging genomic methods towards the discovery of novel genetic alterations in medulloblastoma (MB)Opens in a New Tab.

Non-Hodgkin Lymphoma

CGCI initiated the Non-Hodgkin Lymphoma Project to elucidate the mutation spectrums of the two most abundant forms of non-Hodgkin lymphoma (NHL)Opens in a New Tab: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).

Last updated: March 25, 2016